Optimizing Skyrizi Prior Authorization for Psychiatry Practices

While Skyrizi (risankizumab) is an IL-23 inhibitor primarily indicated for autoimmune conditions, understanding its prior authorization landscape is crucial for psychiatry practices managing patients with complex comorbidities.

Revenue cycle directors and prior authorization coordinators in psychiatry frequently navigate complex patient profiles. When patients under psychiatric care also receive medications like Skyrizi for other conditions, the prior authorization process requires meticulous coordination across specialties. Klivira's platform is designed to streamline these intricate workflows.

Skyrizi (Risankizumab): An Overview for Integrated Care Teams

Skyrizi, known generically as risankizumab, is an IL-23 inhibitor manufactured by AbbVie. Its FDA-approved indications include plaque psoriasis, psoriatic arthritis, and Crohn's disease. It is not indicated for the treatment of primary psychiatric conditions, and its use is typically managed by specialists such as dermatologists, rheumatologists, and gastroenterologists.

Navigating Prior Authorization for Non-Psychiatric Medications in Behavioral Health Settings

Psychiatry practices, especially within integrated health systems, may encounter prior authorization requests for medications like Skyrizi when managing patients with comorbid autoimmune conditions. While a psychiatrist would not typically initiate a Skyrizi prescription, their team may be involved in coordinating care or understanding the patient's overall medication regimen, which impacts the holistic prior authorization process.

General Prior Authorization Requirements for Skyrizi

Confirmed diagnosis for an FDA-approved indication (e.g., plaque psoriasis, psoriatic arthritis, Crohn's disease) documented with objective clinical findings.
Documentation of failed trials or contraindications to preferred first-line or step-therapy agents, as per payer-specific medical policies.
Severity of condition, often assessed by disease-specific scoring systems (e.g., PASI for psoriasis, CDAI for Crohn's disease).
Absence of contraindications as outlined in the drug's prescribing information.

The Intersection of Psychiatric and Autoimmune Care

Patients with chronic autoimmune diseases often experience co-occurring mental health conditions. This necessitates integrated care models where psychiatric teams collaborate with other specialists. In such scenarios, efficient prior authorization for all medications, including specialty drugs like Skyrizi, becomes critical to ensure continuity of care and prevent treatment delays for the patient's full spectrum of health needs.

Klivira's Role in Multi-Specialty Prior Authorization

Klivira's platform provides a centralized solution for managing prior authorizations across diverse specialties, including psychiatry. By integrating with EMRs and payer portals, Klivira streamlines the submission and tracking of PA requests for complex patient cases, regardless of the prescribing specialty. This ensures that all necessary documentation, from DSM-5-TR diagnoses to specialty drug requirements, is managed efficiently.

Mitigating Denials: Focus on Medical Necessity and Approved Indications

A primary reason for prior authorization denials for drugs like Skyrizi in an inappropriate context would be a lack of documented medical necessity for an FDA-approved indication. For psychiatry teams, understanding that Skyrizi is not indicated for psychiatric disorders is key. Klivira's intelligent workflows help flag potential issues, guiding teams to ensure that PA submissions align with payer medical policies and the drug's approved uses, preventing denials based on off-label or unsubstantiated indications.

Frequently asked questions

Is Skyrizi (risankizumab) used to treat psychiatric conditions?

No, Skyrizi (risankizumab) is an IL-23 inhibitor approved for autoimmune conditions such as plaque psoriasis, psoriatic arthritis, and Crohn's disease. It is not indicated for the treatment of any primary psychiatric disorders.

Why would a psychiatry practice encounter a prior authorization for Skyrizi?

Psychiatry practices, particularly those in integrated health systems, may encounter Skyrizi prior authorizations when managing patients who also have comorbid autoimmune conditions. While the psychiatrist would not prescribe Skyrizi, their team might coordinate care or manage the patient's overall medication profile.

What documentation is typically required for Skyrizi prior authorization?

Prior authorization for Skyrizi generally requires documentation of a confirmed diagnosis for an FDA-approved indication, evidence of failed trials with or contraindications to other therapies, and objective measures of disease severity. This documentation is specific to its approved uses, not psychiatric conditions.

How does Klivira support prior authorization for specialty drugs like Skyrizi in a multi-specialty environment?

Klivira streamlines prior authorization for all medications by integrating with EMRs and payer portals. For specialty drugs like Skyrizi, Klivira ensures that all required clinical documentation, regardless of the prescribing specialty, is accurately submitted and tracked, facilitating efficient approval processes across integrated care teams.

What are common reasons for Skyrizi prior authorization denials in a psychiatric context?

The most common denial reason for Skyrizi in a psychiatric context would be a lack of medical necessity for an FDA-approved indication. If submitted for a psychiatric diagnosis, it would be considered off-label and not supported by payer medical policies, leading to a denial.